DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Amendment
This action is in response to the Amendment filed on 12/2/2025.
Claims 1-25 are pending.
Claims 1-21 withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim.
Claim 22-25 are being examined.
Response to Arguments
Applicant's arguments with respect to claims 22-25 have been considered but are moot in view of the new grounds of rejection as necessitated by the amendments.
Rejections under 35 U.S.C. 103 - U.S. Patent No. 7,848,620 to Ryu in view of U.S. Patent No. 8,442,620 to Silipo and further in view of U.S. Patent Pub. No. 20160045747 to Jiang, U.S. Patent Pub. No. 2005267555 to Marnfeldt.
Independent claims 22 and 25 have been now amended to recite:
“a lead an insulated body comprising an open-coiled structure with a central void, which promotes tissue ingrowth…”
Applicant asserts that Ryu, Silipo and Jiang fail to disclose, teach or suggest a lead comprising an insulated body comprising an open-coiled structure with a central void, which promotes tissue ingrowth and a conductive distal anchor as is recited in claim 22.
Applicant arguments have been considered and are persuasive and therefore the rejection has been withdrawn. However, upon further search and consideration, the claims are now rejected as discussed in the current office action below.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 22, 24 and 25 are rejected under 35 U.S.C. 103 as being unpatentable over Ryu et al (U.S. Patent Number: US 7,848,821 B1, hereinafter “Ryu”, cited in IDS filed 07/30/2024) in view of Bonde et al (U.S. Patent Application Publication Number: US 2007/0255368 A1, hereinafter “Bonde”) and Silipo et al (U.S. Patent Number: US 8,442,620 B2, hereinafter “Silipo”, cited in IDS filed 07/30/2024), and in further view of Jiang et al (U.S. Patent Application Publication Number: US 2016/0045747 B2, hereinafter “Jiang”- PREVIOUSLY CITED).
Regarding claims 22, 24 and 25, Ryu teaches a system for testing, positioning, introducing and deploying a lead for percutaneous peripheral nerve stimulation, the system comprising:
a lead comprising an insulated lead body (e.g. 50 Figs.7-12, Col. 5 lines 61-62) a conductive distal anchor (e.g. 50, 50a-50d Figs. 7-12, col. 5, lines 61-67: insulated lead body 50 comprising electrode distal end 35 and conductive distal anchor 45 for delivering electrical current);
an introducing needle (e.g. 90 Figs. 7-12; col. 5, lines 50-53: push tube) comprising an inner lumen (e.g. 95 Fig 7-12) configured to contain the lead (e.g. 50 Figs. 7-11), and wherein the introducing needle comprises a distal portion forming a terminal opening (e.g. 100 Fig. 7-12 Col. 6 lines 5-30 col. 6, lines 20-29; col. 7, line 62-col. 8, line 6);
an introducing sheath (e.g. 25 Figs. 7-12; col. 5, line 53), comprising an inner lumen configured to contain the introducing needle (e.g. 90 Figs. 7-12) and the conductive distal anchor (e.g. 45/45a-d Figs. 7-12) of the stimulation lead ( e.g. 50/50a-d Figs. 7-12) and wherein the introducing sheath comprises a distal portion of the introducing sheath forming a terminal opening of the introducing sheath (Figs. 7-12 show the introducing sheath 25 comprises a distal end 20, which comprises a terminal opening that permits deployment of the introducing needle and stimulation lead out of the inner lumen 40 and out the distal end 20; col. 6, lines 20-29; col. 7, line 62-col. 8, line 6);
Ryu further teaches that a portion of the conductive distal anchor (e.g. 45/45a-d Figs. 7-12) protrudes from the lumen of the introducing needle, forming a bend (Ryu shows the anchor is a hook/barb, and since a hook inherently comprises a bend, said bend clearly shown in Figs. 7-12, then the conductive distal anchor comprises a bend) over a first edge of the terminal opening of the introducing needle (e.g., Fig. 10 shows conductive distal anchor 45a having a bend that is over the opening of introducing needle 90).
Ryu does not specifically teach that the insulated lead body comprises an open-coiled structure with a central void which promotes tissue ingrowth.
In a similar field of endeavor, Bonde teaches an implantable medical electrical lead for applying electrical stimulation energy and further teaches an insulated lead body (e.g. 44 Fig. 3) comprises an open-coiled structure (e.g. [0028]: an electrically non-conductive material 42 covering a section of the wire 40, the wire coil 40 can be closely wound as shown, or in alternative embodiments, individual windings of the wire coil 40 can be longitudinally spaced. The coiled nature of the wire 40 can further be continued along a majority of the wire's length) with a central void (e.g. 52 Fig.3 [0028]: the coil configuration generates or defines an internal passage 52) which to provide strain relief. Therefore it would have been obvious to a person having ordinary skill in the art before the effective filing date of the invention to modify the insulated lead body in the teachings of Ryu to have an open coiled structure as taught by Bonde in order to provide the predictable results of providing strain relief and further the textured surface of the coiled insulated lead body and the internal passage will promote tissue growth.
Further Silipo teaches that it is known in the art of fixation leads having an integrated electrode to include a fixation shape appropriate for the medical application, such as a bent barb or tine 220 similar to Ryu’s (Silipo’s Figs. 1A-1B), which can alternatively be an open-coiled helical shape 220’ also having a bent end (Silipo’s Figs. 2A-2B), which provide the same purpose of engagement and fixation into target tissue (col. 5, line 58-col. 6, line 8; col. 8, lines 20-42). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modified the conductive distal anchor of Ryu in view of Bonde to have a bent anchoring shape as shown by any of Ryu or Silipo and including an open-coiled helical shape, for the purpose of providing the fixation shape appropriate for fixation at the tissue site based on the desired medical application. (Note: for the sake of compact prosecution, Silipo’s teachings are being included in the rejection to show an open coiled bent anchor).
Further Ryu teaches that a plurality of stimulation leads may be retained by the introducing needle that is retained by the introducing sheath, for different purposes, such as for positioning a plurality of conductive distal anchors in different implantation sites (50a-d above refer to a plurality of stimulation leads; the different stimulation leads may be deployed in a staggered manner so that their respective conductive distal anchors engage different tissue sites, col. 7, lines 21-36). Ryu is relied upon to teach that it is reasonable to include an introducing sheath comprising an introducing needle comprising a plurality of deployable structures within the introducing needle, teaching that the introducing sheath is configured to contain a series of tubular nesting components, which comprises the deployable conductive distal anchor. However Ryu does not teach a testing needle with an inner lumen and wherein a distal portion of the testing needle comprises one or more bevels and wherein the testing needle comprises an outer diameter configured to be received by the inner lumen of the introducing sheath, wherein the testing needle is configured for electrical stimulation testing prior to introduction of the lead, and wherein the testing needle and the introducing needle are not received by the introducing sheath concurrently, such that the testing needle is removed from the introducing sheath prior to insertion of the introducing needle.
In a similar field of endeavor, Jiang teaches that it is well known to use an introducer sheath, a stylet and a beveled testing needle (i.e. foramen needle Fig. 9) for localization of a target and subsequent implantation of the lead wherein the testing needle comprises an inner lumen (i.e. [0099]: The foramen needle and stylet are used for locating the correct sacral foramen or implant lead and subsequent acute stimulation testing, therefore the foramen needle has a lumen for the stylet) an outer diameter configured to be received by an inner lumen of an introducing sheath (i.e. introducer), wherein the testing needle and the introducing needle (i.e. directional guide) are not received by the introducing sheath concurrently (e.g. [0099], Fig. 9). Therefore it would have been obvious to a person having ordinary skill in the art before the effective filing date of the invention to modify the teachings of Ryu in view of Bonde and Silipo to further include a testing needle for electrical stimulation testing prior to introduction of the lead as taught by Jiang and wherein the testing needle and the introducing needle are not received by the introducing sheath concurrently, such that the testing needle is removed from the introducing sheath prior to insertion of the introducing needle (i.e. push tube) in order to provide the predictable results of being able to accurately determine the target location. (Note: as discussed in the office action mailed on 9/2/2025, the claims are directed to an apparatus that comprises the claimed elements and the order of introduction, testing and removal of the testing needle and lead is intended use, furthermore the claims do not recite any specific dimensions for the claimed elements).
Claim 23 is rejected under 35 U.S.C. 103 as being unpatentable over Ryu et al (U.S. Patent Number: US 7,848,821 B1, hereinafter “Ryu”, cited in IDS filed 07/30/2024) in view of Bonde et al (U.S. Patent Application Publication Number: US 2007/0255368 A1, hereinafter “Bonde”) and Silipo et al (U.S. Patent Number: US 8,442,620 B2, hereinafter “Silipo”, cited in IDS filed 07/30/2024), and Jiang et al (U.S. Patent Application Publication Number: US 2016/0045747 B2, hereinafter “Jiang”- PREVIOUSLY CITED) and in further view of Marnfeldt et al (U.S. Patent Application Publication Number: US 2005/267555 A1, hereinafter “Marnfeldt”- PREVIOUSLY CITED).
Regarding claim 23, Ryu in view of Bonde and Silipo and Jiang teach the claimed invention as discussed above, but does not specifically teach that the distal portion of the introducing needle comprises one or more bevels.
Marnfeldt teaches that it is well known for engagement tools for implantable medical devices to have beveled edges (e.g. 310 Fig 3A). Therefore, it would have been obvious to a person having ordinary skill in the art before the effective filing date of the invention to modify the introducing needle (i.e. push tube) of Ryu to have beveled edges as shown by the needle 310 of Marnfeldt’s teachings of in order to provide the predictable results of easily conforming to the feature 75 of the electrode 10 of Ryu (e.g. Figs 4-6) and being able to easily navigate through the tissue.
Conclusion
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.
Zarembo et al (U.S. Patent Application Publication Number: US 2004/0054390 A1, hereinafter “Zarembo”) teaches an implantable medcial lead comprising insulated lead body comprises an open-coiled structure with a central void (e.g. Fig. 8).
Applicant's amendment necessitated the new grounds of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to MALLIKA DIPAYAN FAIRCHILD whose telephone number is (571)270-7043. The examiner can normally be reached Monday- Friday 8 am-5pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, BENJAMIN KLEIN can be reached at 571-270-5213. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/MALLIKA D FAIRCHILD/Primary Examiner, Art Unit 3792